Journals / Erciyes Tıp Dergisi / 2014 / Cilt: 36 - Sayı: 4

Primer ve metastatik prostat adenokarsinomlarında C-ErbB-2 ekspresyonu, amplifikasyonu ve prognostik değerinin değerlendirilmesi

Evaluation of c-erbB-2 expression, amplifcation, and prognostic value in primary and metastatic prostate adenocarcinomas

Pages
156–160
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Therefore, this marker may be helpful for planning therapy.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The c-erbB-2 gene codes for a membrane receptor protein that is homologous to the epidermal growth factor receptor.
📊
Key Findings & Data:The prognostic role of c-erbB-2 expression andgene amplifcation in prostate carcinoma is still controversial.
💡
Conclusion & Impact:Therefore, this marker may be helpful for planning therapy.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: The c-erbB-2 gene codes for a membrane receptor protein that is homologous to the epidermal growth factor receptor. It has been established as a prognostic factor in breast and other cancers. The prognostic role of c-erbB-2 expression andgene amplifcation in prostate carcinoma is still controversial. In this study, we searched for c-erbB-2 overexpression and geneamplifcation in primary and metastatic prostate carcinomas and their correlation with tumor grade, age, and survival.Material and Methods: c-erbB-2 protein overexpression was analyzed on 59 prostate carcinomas, including 44 primary and 15metastatic prostate carcinomas, by immunohistochemistry and fuorescence in situ hybridization analysis.Results: When divided into two Gleason grade categories, there were 20 low-grade and 24 high-grade cases in the primary prostate carcinoma cases. C-erbB-2 overexpression was detected in 13.6% of primary and in 60% of metastatic prostate carcinomas.The overexpression was correlated with Gleason score (p=0.001) and clinical outcome but not with age (p>0.05). None of thecases showed HER-2 amplifcation by FISH.Conclusion: In this study, c-erbB-2 protein overexpression was associated with high grade and advanced pathological stage. Additionally, it was also associated with metastatic prostate tumors. These fndings support that this marker indicates a potentiallyaggressive clinical course and metastasis. Therefore, this marker may be helpful for planning therapy.

Özet

Amaç: C-erbB-2 geni epidermal büyüme faktörü reseptörü ile homolog olan bir membran reseptör proteinini kodlar. Meme kanseri ve diğer kanserlerin bir prognostik faktörü olduğu belirlenmiştir. Prostat karsinomunda c-erbB-2 ekspresyonunun ve gen amplifikasyonunun prognostik rolü hâlâ tartışmalıdır. Bu çalışmada, primer ve metastatik prostat karsinomlarında c-erbB-2 aşırı ekspresyonunu ve gen amplifikasyonunu ve bunların tümörün evresi, yaş, ve sağkalım ile korelasyonlarını araştırdık. Materyal ve Metot: c-erbB-2 protein aşırı ekspresyonu 44 primer ve 15 metastatik prostat karsinomu olmak üzere 59 prostat karsinomunda immünohistokimya ve floresan in situ hibridizasyon analizleri kullanılarak incelendi. Bulgular: İki Gleason grade kategorisine ayrıldığı zaman, primer prostat karsinomu olgularında 20 düşük-grade ve 24 yüksek-grade olgu vardı. C-erbB-2 aşırı ekspresyonu, prostat karsinomlarında primer olanların %13.6sında ve metastatik olanların %60ında tespit edildi. Aşırı ekspresyon Gleason skoru (p=0.001) ve klinik sonuç ile ilişkiliydi ancak yaşla ilişkili değildi (p>0.05). Hiçbir olgu FISH ile HER-2 amplifikasyonu göstermedi. Sonuç: Bu çalışmada, c-erbB-2 proteini aşırı ekspresyonu yüksek grade ve ileri patolojik evre ile ilişkili idi. Ek olarak, metastatik prostat tümörü ile de ilişkiliydi. Bu bulgular, bu belirtecin bir potansiyel agresif klinik seyre ve metastaza işaret ettiğini desteklemektedir. Bu nedenle, bu belirteç tedavi planlaması için yararlı olabilir.

🔖

Cite This Article

İZOL, V., BAĞIR, E., ZORLUDEMİR, S., TANSUĞ, Z., ŞEYDAOĞLU, G., AÇIKALIN, A., GÖNLÜŞEN, G., ERDOĞAN, Ş. (2022). Primer ve metastatik prostat adenokarsinomlarında C-ErbB-2 ekspresyonu, amplifikasyonu ve prognostik değerinin değerlendirilmesi. Erciyes Tıp Dergisi, Cilt: 36 - Sayı: 4, 156–160. https://ajindex.com/articles/502337

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. McCann A, Dervan PA, Johnston PA, Gullick WJ, Carney DN. c- erbB-2 oncoprotein expression in primary human tumors. Cancer 1990
  2. 65(1): 88-92. [CrossRef] 2. Disis ML, Cheever MA. HER-2/neu protein: a target for antigen- specifc immunotherapy of human cancer. Adv Cancer Res 1997
  3. [CrossRef] 3. Ross JS, Fletcher JA. Her-2/neu (c-erbB-2) gene and protein in breast cancer. Am J Clin Pathol 1999
  4. 112(Suppl): 53-67. 4. Sütterlin MW, Haller A, Gassel AM, Peters K, Caffer H, Dietl J. The correlation of c-erbB-2 oncoprotein and established prognostic factors in human breast cancer. Anticancer Res 2000
  5. 20(6): 5083-8. 5. Tetu B, Brisson J. Prognostic signifcance of HER-2/neu oncoprotein expression in node-positive breast cancer. The infuence of the pattern of immunostaining and adjuvant therapy. Cancer 1994
  6. 73(9): 2359- 65. [CrossRef] 6. Uehara T, Kaneko Y, Kanda N, Yamamoto T, Higashi Y, Nomoto C, et al. c-erbB-2 and c-erbB-1 (ear-1) gene amplifcation and c-erbB-2 protein expression in Japanese breast cancers: their relationship to the histology and other disease parameters. Cancer Res 1990
  7. 81 (6-7): 620-4. 7. Perren TJ. c-erbB-2 oncogene as a prognostic marker in breast can- cer. Br J Cancer 1991
  8. 63(3): 328-32. [CrossRef] 8. Sadasivan R, Morgan R, Jennings S, Austenfeld M, Van Veldhuizen P, Stephens R, et al. Overexpression of HER-2/NEU may be an indica- tor of poor prognosis in prostate cancer. J Urol 1993
  9. 150(1): 126- 31. 9. Berner A, Nesland JM, Waehre H, Silde J, Fossa SD. Hormone resistant prostatic adenocarcinoma. An evaluation of prognostic factors in pre-and post-treatment specimens. Br J Cancer 1993
  10. 68(2): 380-4. [CrossRef] 10. Kuhn EJ, Kurnot RA, Sesterhenn IA, Chang EH, Moul JW. Expression of the c-erbB-2 (HER-2/neu) oncoprotein in human prostatic car- cinoma. J Urol 1993
  11. 150(5 Pt 1): 1427-33. 11. Ross JS, Sheehan CE, Hayner-Buchan AM, Ambros RA, Kallakury BV, Kaufman RP Jr, et al. Prognostic signifcance of HER-2/neu gene amplifcation status by fuorescence in situ hybridization of prostate carcinoma. Cancer 1997
  12. 79(11): 2162-70. [CrossRef] 12. Montironi R, Mazzucchelii R, Barbisan F, Stramazzotti D, Santinelli A, Scarpelli M, et al. HER2 expression and gene amplifcation in pT2 Glea- son score 6 prostate cancer incidentally detected in cystoprostatectomies: comparison with clinically detected androgen-dependent androgen-inde- pendent cancer. Human Pathol 2006
  13. 37(9): 1137-44. [CrossRef] 13. Fossa A, Lilleby W, Fossa SD, Gaudernack G,